[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Soft-tissue sarcomas (STS) are usually sensitive to doxorubicine and/or ifosfamide. When tumors become refractory to these two drugs, chemotherapeutic options are limited. All the drugs tested generally yield occasional or negligible response, with response rates lower than 20% and a poor duration of response. No second-line chemotherapy have been clearly adopted. In vitro synergistic cytotoxicity has been reported with gemcitabine and docetaxel combination. Promising anti-tumor activity has been described with gemcitabine alone, docetaxel alone or these two drugs in combination These treatments were generally well tolerated. The best response have been observed in leiomyosarcomas. According to these results, gemcitabine and docetaxel combination might be of interest in STS. However, a phase III study is required to better evaluate the real advantage of this treatment.
Bay
Jacques-Olivier
JO
Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand. Olivier.bay@cjp.fr
Cabrespine
Aurélie
A
Gilliot
Olivier
O
Bailly
Corine
C
Vincent
Catherine
C
Mishellany
Florence
F
Gimbergues
Pierre
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077143:Docetaxel; D006801:Humans; D012509:Sarcoma / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage*; D000093542:Gemcitabine
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine